Aclaris Therapeutics Inc (ACRS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aclaris Therapeutics Inc stock (ACRS) is currently trading at $3.59. Aclaris Therapeutics Inc PS ratio (Price-to-Sales) is 57.09. Analyst consensus price target for ACRS is $8.29. WallStSmart rates ACRS as Sell.
- ACRS PE ratio analysis and historical PE chart
- ACRS PS ratio (Price-to-Sales) history and trend
- ACRS intrinsic value — DCF, Graham Number, EPV models
- ACRS stock price prediction 2025 2026 2027 2028 2029 2030
- ACRS fair value vs current price
- ACRS insider transactions and insider buying
- Is ACRS undervalued or overvalued?
- Aclaris Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ACRS Piotroski F-Score and Altman Z-Score
- ACRS analyst price target and Smart Rating
Aclaris Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Aclaris Therapeutics Inc (ACRS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aclaris Therapeutics Inc (ACRS) Key Strengths (1)
78.50% of shares held by major funds and institutions
Supporting Valuation Data
Aclaris Therapeutics Inc (ACRS) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -85.90%, a shrinking business
Very expensive at 57.1x annual revenue
Premium pricing at 4.3x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Aclaris Therapeutics Inc (ACRS) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (57.09), Price/Book (4.33) suggest expensive pricing. Growth concerns include Revenue Growth at -85.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -50.20%, Operating Margin at -1725.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -50.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -85.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ACRS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ACRS's Price-to-Sales ratio of 57.09x trades at a deep discount to its historical average of 204.53x (54th percentile). The current valuation is 96% below its historical high of 1579.15x set in Jan 2018, and 1772% above its historical low of 3.05x in Nov 2023. Over the past 12 months, the PS ratio has expanded from ~9.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aclaris Therapeutics Inc (ACRS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aclaris Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 8M with 86% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 25M in cash.
Spending 212% of revenue (17M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 86% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -13M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aclaris Therapeutics Inc.
Bottom Line
Aclaris Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(54 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:40:18 AM
About Aclaris Therapeutics Inc(ACRS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.